The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global transfection technologies market is expected to reach a value of US$ 1.5 Billion by 2026, exhibiting a CAGR of 8.44% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Transfection technology refers to the process of artificially introducing nucleic acid, such as Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA) and oligonucleotides, into the cells. It is introduced using various physical, chemical and biological methods, which can assist in modifying certain properties of the cell. It involves various methods, including cotransfection, electroporation, cationic lipid transfection and in-vivo transfection. This process is commonly used for various genomic studies that include gene expression, screening, RNA interference and Vivo research, along with the bioproduction of viruses and proteins.
The increasing prevalence of cancer and various chronic lifestyle diseases is one of the key factors driving the growth of the market. Furthermore, widespread adoption of reagent-based methods is also providing a boost to the market growth. In comparison to the traditionally used techniques, reagent-based transfection is less complicated to administer and more cost-effective. In line with this, instrument-based methods, such as biolistic technology, microinjection and laserfection, are also gaining immense traction across the globe. Various technological advancements in cell research and therapeutic discovery are acting as another major growth-inducing factor. In line with this, research in gene transfer is majorly performed under in-vivo conditions for the development of novel therapeutic drugs and various other applications. Other factors, including increasing investments by both government and private organizations to develop large scale transfection facilities, along with extensive research and development (R&D) activities in the field of protein therapeutics, are projected to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global transfection technologies market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product type, application, transfection method, technology and end-user.
Breakup by Product Type:
Breakup by Application:
Breakup by Transfection Method:
Breakup by Technology:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product Type, Application, Transfection Method, Technology, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Agilent Technologies Inc., Bio-RAD Laboratories Inc., Lonza Group AG, Maxcyte Inc., Mirus Bio LLC, Polyplus Transfection, Promega Corporation, Roche Holding AG, Sigma-Aldrich Corporation and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at